Biomarker testing is key to unlocking precision medicine.
Biomarkers are often used to help determine the best treatment for a patient, but not all communities are benefitting from the latest advancements in biomarker testing and precision medicine.
Progress in improving cancer outcomes increasingly involves the use of precision medicine. Biomarker testing is an important step for accessing precision medicine including targeted therapies that can lead to improved survivorship and better quality of life for cancer patients. But without action to expand coverage of and access to biomarker testing, advances in precision medicine could increase existing disparities in cancer outcomes by race, ethnicity, income, and geography.
ACS CAN is working to expand insurance coverage of comprehensive biomarker testing.
Legislation enacted: AZ, IL, LA, RI, KY, NM, MD, GA, AR* Legislation passed in 2023: TX, OK, MN Legislation introduced in 2023: CA,CT, CO, FL, MA, ME, NV, NY, OH, PA (expected)
ALBANY, NY – MAY 30, 2023 – Yesterday, Texas Governor Greg Abbott signed Senate Bill 989 into law, making Texas the 11 th state to expand access to biomarker testing. New York is considering comparable legislation through Assembly Bill 1673 / Senate Bill 1196. The American Cancer Society Cancer
SAINT PAUL, Minn. – Today, Governor Tim Walz signed legislation that will ensure biomarker testing is covered by more insurance plans, including Medicaid, when patients need it. The new law will enable more Minnesotans to benefit from biomarker testing, a critical step in accessing precision medicine treatments that can lead to fewer
ALBANY, NY – MAY 19, 2023 – Every year on May 20, patients and providers celebrate the invaluable work of clinical trials in the effort to eradicate all suffering and death from cancer. In observance of Clinical Trials Day on the 20th, the American Cancer Society Cancer Action Network (ACS
ALBANY, NY – MAY 17, 2023 – Earlier today, oncologists and cancer survivors from across New York gathered at the Capitol to answer lawmakers’ questions about biomarker testing and ask for their support of Senate Bill 1196 / Assembly Bill 1673. This legislation, which is being sponsored by Asm. Pamela
Biomarker testing is key to unlocking precision medicine. However, coverage for guideline-recommended biomarker tests is not universal and can be a barrier to cancer patients accessing treatments that can lead to improved survival and quality of life.
Pharmacogenomic (PGx) testing is a component of precision medicine that involves examining a patient’s inherited genes to detect variations that may impact the way a drug is broken down, absorbed and used within the body.